1. Pink Sheet
  3. >>Clinical Trials

US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Guidance Targets ‘Multiplicity Problem’

 
• By Alaric DeArment

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

• Source: Shutterstock

More than five years after releasing its draft guidance on clinical trials with multiple endpoints, the US Food and Drug Administration has put out a final version of that guidance, with an eye toward ensuring that in particular, studies with more than one independent primary endpoint do not run the risk of producing results with false positives or false negatives about a drug’s efficacy.

The FDA released the final guidance on 21 October, having put out a draft version of the guidance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.